Pay in 4 interest-free payments of $6.44 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
THE PUBLIC DEBATE AROUND GLP-1 AND DHB SIGNALS, SKEPTICISM, AND SATURATION As public interest in GLP-1 has grown, so too has the conversation about what these strategies represent for the future of wellness
The high cost of brand-name drugs is due to R&D, marketing, and patent protection
BMO Capital Markets analysts expect a slow launch, however, writing in a note to investors about challenges including a black box warning for risk of acute adrenal insufficiency or adrenal crisis with inadequate concomitant glucocorticoid therapy. The firm said it anticipates broad commercial access will not happen until the second half of 2025
Injections require a clinic visit and may not suit patients with needle phobia or scheduling constraints
Unclear: Reassess
But large, heavy meals can feel like too much on GLP-1
US$ 21.36
US$ 25.89
US$ 23.78
